Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12621000713897
Ethics application status
Approved
Date submitted
22/02/2021
Date registered
8/06/2021
Date last updated
8/06/2021
Date data sharing statement initially provided
8/06/2021
Type of registration
Prospectively registered
Titles & IDs
Public title
Lipoprotein (a) as a risk factor for restenosis in patients with aortoiliac disease undergoing endovascular management
Query!
Scientific title
Lipoprotein (a) as a risk factor for restenosis in patients with aortoiliac disease undergoing endovascular management
Query!
Secondary ID [1]
303524
0
None
Query!
Universal Trial Number (UTN)
U1111-1265-2213
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Aortoiliac occlusive disease
320853
0
Query!
Peripheral arterial disease
320856
0
Query!
Stenosis
320857
0
Query!
Condition category
Condition code
Cardiovascular
318676
318676
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
This is an interventional, prospective study to assess the relationship between serum Lp(a) concentration and the development of restenosis in 60 patients with aortoiliac PAD undergoing endovascular therapy up to 12 months post endovascular therapy. The patient's procedure will be conducted as per usual standard of care. Blood sample will be collected at baseline, post-procedure and 1-, 6- and 12-months post-procedure.
Query!
Intervention code [1]
319807
0
Diagnosis / Prognosis
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
326618
0
Lp (a) measurement using blood sample
Query!
Assessment method [1]
326618
0
Query!
Timepoint [1]
326618
0
30-days post-procedure
Query!
Primary outcome [2]
327617
0
Stent patency using duplex ultrasound
Query!
Assessment method [2]
327617
0
Query!
Timepoint [2]
327617
0
30-days post procedure
Query!
Secondary outcome [1]
392153
0
• Primary patency at 6 months post index procedure using duplex ultrasound
Query!
Assessment method [1]
392153
0
Query!
Timepoint [1]
392153
0
6-months post procedure
Query!
Secondary outcome [2]
395755
0
Primary patency at 12 months post procedure using duplex ultrasound
Query!
Assessment method [2]
395755
0
Query!
Timepoint [2]
395755
0
12 months post procedure
Query!
Secondary outcome [3]
395757
0
Secondary patency using duplex ultrasound
Query!
Assessment method [3]
395757
0
Query!
Timepoint [3]
395757
0
12 months post procedure
Query!
Secondary outcome [4]
396295
0
Binary restenosis using duplex ultrasound
Query!
Assessment method [4]
396295
0
Query!
Timepoint [4]
396295
0
30 days post index procedure
Query!
Secondary outcome [5]
396296
0
Rate of Target lesion revascularisation determined from hospital records
Query!
Assessment method [5]
396296
0
Query!
Timepoint [5]
396296
0
30 days post-index procedure
Query!
Secondary outcome [6]
396297
0
CRP, FBC and lipid profile (HDL, LDL, Triglycerides, apoprotein B) levels from blood sample
Query!
Assessment method [6]
396297
0
Query!
Timepoint [6]
396297
0
30 days post index procedure
Query!
Eligibility
Key inclusion criteria
1. Patients greater than or equal to 18 years of age
2. The participant has provided written informed consent
3. Evidence of TASC B, C or D lesions (TASC II classification)
4. Patients undergoing endovascular therapy for aortoiliac occlusive disease
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Patients less than 18 years of age
2. Pregnant women or women of childbearing potential who are not using an effective method of contraception
3. Uncontrolled hypertension
4. TASC A lesion
5. Patients requiring open procedure
6. Extensive common femoral artery disease or multiple groin procedures
7. Contraindication to antiplatelet use
8. Occluded superficial and profunda femoral arteries
9. Noncompliance with protocol requirements
10. Previous or planned surgical or interventional procedure within 14 days before or 30 days after the index procedure
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
The sample size was determined by aiming to have adequate power to test out hypothesis that Lp(a) greater than or equal to 50 mg/dL was associated with increased rates of restenosis. Based on previous studies and publications.
Descriptive statistics will be presented for all the primary and secondary endpoints.
For quantitative variables, the mean values, standard deviation, maximum and minimum, as well as the 95% CI (confidence interval) for the mean will be calculated when relevant.
Kaplan Meier estimates will be performed to measure clinical endpoints including primary patency and binary restenosis.
Cox proportional hazard analyses will be used to assess the association between serum Lp(a) with outcomes of interest, adjusted for other risk factors.
Further analysis will be conducted by stratifying patients into two groups. Group A will have normal baseline Lp(a) levels +/- inflammatory markers; Group B will have high levels of Lp(a) +/- inflammatory markers. In this study, LP(a) levels will be defined as high if serum Lp(a) are greater than or equal to 0.5g/L and as low Lp(a) if less than 0.5g/L.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
30/06/2021
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
30/06/2022
Query!
Actual
Query!
Date of last data collection
Anticipated
30/06/2023
Query!
Actual
Query!
Sample size
Target
60
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
WA
Query!
Recruitment hospital [1]
18807
0
Royal Perth Hospital - Perth
Query!
Recruitment postcode(s) [1]
33255
0
6000 - Perth
Query!
Funding & Sponsors
Funding source category [1]
307946
0
Hospital
Query!
Name [1]
307946
0
Royal Perth Hospital Vascular Department
Query!
Address [1]
307946
0
Department of Vascular Surgery
Level 6 North Block
Royal Perth Hospital
180 Wellington Street
Perth WA 6000
Query!
Country [1]
307946
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Royal Perth Hospital
Query!
Address
Department of Vascular Surgery
Level 6 North Block
Royal Perth Hospital
180 Wellington Street
Perth WA 6000
Query!
Country
Australia
Query!
Secondary sponsor category [1]
308663
0
None
Query!
Name [1]
308663
0
Query!
Address [1]
308663
0
Query!
Country [1]
308663
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
307938
0
Royal Perth Hospital Human Research Ethics Committee
Query!
Ethics committee address [1]
307938
0
197 Wellington Street
Perth WA 6000
Query!
Ethics committee country [1]
307938
0
Australia
Query!
Date submitted for ethics approval [1]
307938
0
17/11/2020
Query!
Approval date [1]
307938
0
12/01/2021
Query!
Ethics approval number [1]
307938
0
RGS4460
Query!
Summary
Brief summary
Peripheral arterial diseases (PADs) are a collection of chronic occlusive conditions affecting adults, which predominately occur due to atherosclerosis and affects approximately 15% of the Australian population. Lipoprotein (a) [Lp(a)] is an emerging risk factor for PAD and atherosclerosis. Multiple studies have demonstrated a causal relationship between elevated Lp(a) and the development of atherosclerotic cardiovascular disease, calcific aortic valve disease and inflammation. The role of Lp(a) in restenosis in PAD is unclear, however Lp(a) is implicated in promoting atherosclerosis progression, thrombosis and inflammation which are all pathological processes thought to be critical in stimulating PAD progression and the need for surgical intervention. The primary aim of this study is to assess the relationship between serum Lp(a) concentration and the development of restenosis in 60 patients with aortoiliac PAD undergoing endovascular therapy up to 12 months post endovascular therapy.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
108986
0
A/Prof Patrice Mwipatayi
Query!
Address
108986
0
Royal Perth Hospital
Department of Vascular Surgery
Level 6, North Block,
180 Wellington Street
Perth, WA, 6000
Query!
Country
108986
0
Australia
Query!
Phone
108986
0
+61 8 9224 2191
Query!
Fax
108986
0
Query!
Email
108986
0
[email protected]
Query!
Contact person for public queries
Name
108987
0
A/Prof Patrice Mwipatayi
Query!
Address
108987
0
Royal Perth Hospital
Department of Vascular Surgery
Level 6, North Block,
180 Wellington Street
Perth, WA, 6000
Query!
Country
108987
0
Australia
Query!
Phone
108987
0
+61 8 9224 2191
Query!
Fax
108987
0
Query!
Email
108987
0
[email protected]
Query!
Contact person for scientific queries
Name
108988
0
A/Prof Patrice Mwipatayi
Query!
Address
108988
0
Royal Perth Hospital
Department of Vascular Surgery
Level 6, North Block,
180 Wellington Street
Perth, WA, 6000
Query!
Country
108988
0
Australia
Query!
Phone
108988
0
+61 8 9224 2191
Query!
Fax
108988
0
Query!
Email
108988
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
de-identified individual data including demographic data, blood results and follow up data
Query!
When will data be available (start and end dates)?
Data will be available immediately following publication. There is no end date to availability. Data will be available for 5 years after publication and beyond
Query!
Available to whom?
only researchers who provide a methodologically sound proposal
Query!
Available for what types of analyses?
Meta-analyses
Query!
How or where can data be obtained?
access subject to approvals by Principal Investigator email:
[email protected]
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF